Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Greenworks
301260
5
Tuoxin Pharmaceutical Group
301089
(Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -11.34%21.07B | -10.73%91.42B | -23.21%20.82B | -8.56%23.37B | 2.12%23.47B | -11.22%23.77B | -17.73%102.41B | -10.16%27.11B | -21.16%25.55B | -33.78%22.98B |
Operating revenue | -11.34%21.07B | -10.73%91.42B | -19.82%25.05B | -8.90%21.85B | 2.12%23.47B | -11.22%23.77B | -17.73%102.41B | 3.56%31.24B | -26.02%23.98B | -33.78%22.98B |
Cost of revenue | -7.18%10.69B | -6.18%45.44B | -13.02%10.83B | -5.18%11.36B | 3.51%11.74B | -9.06%11.51B | -18.58%48.44B | -20.13%12.45B | -24.52%11.98B | -25.58%11.34B |
Gross profit | -15.25%10.39B | -14.83%45.97B | -31.88%9.98B | -11.53%12.01B | 0.77%11.73B | -13.15%12.26B | -16.95%53.97B | 0.51%14.65B | -17.94%13.57B | -40.21%11.64B |
Operating expense | -5.45%3.02B | 39.86%20.28B | 78.83%8.71B | -4.23%3.2B | 66.44%5.41B | 6.93%3.19B | 23.70%14.5B | 17.21%4.87B | 29.00%3.34B | 27.52%3.25B |
Selling and administrative expenses | -8.98%1.94B | 12.06%9.03B | -26.35%1.71B | 0.83%2.05B | 64.10%3.01B | 15.73%2.13B | 15.09%8.06B | -0.43%2.32B | 26.38%2.04B | 16.31%1.83B |
-General and administrative expense | -8.98%1.94B | 12.06%9.03B | -26.35%1.71B | 0.83%2.05B | 64.10%3.01B | 15.73%2.13B | 15.09%8.06B | -0.43%2.32B | 26.38%2.04B | 16.31%1.83B |
Research and development costs | 10.38%202M | 8.68%789M | 1.87%218M | 4.84%195M | 12.21%193M | 18.83%183M | -8.33%726M | 19.55%214M | -0.53%186M | -21.82%172M |
Depreciation amortization depletion | 0.00%208M | 11.48%816M | 17.32%210M | 1.57%194M | 9.68%204M | 18.18%208M | -18.12%732M | -14.76%179M | -13.18%191M | -22.82%186M |
Provision for doubtful accounts | -140.00%-4M | 545.00%258M | 861.54%250M | --0 | 50.00%-2M | -52.38%10M | -27.27%40M | 23.81%26M | -115.00%-3M | -166.67%-4M |
Other taxes | -28.57%65M | 368.08%3.21B | 1,275.00%2.15B | -222.92%-118M | 266.78%1.09B | -33.09%91M | 94.33%686M | -14.29%156M | 50.00%96M | 331.88%298M |
Other operating expenses | 71.43%-22M | 73.43%3.56B | 150.88%3.58B | -25.75%199M | 28.83%210M | -147.24%-77M | 159.29%2.05B | 93.10%1.43B | 824.14%268M | 308.97%163M |
Operating profit | -18.70%7.37B | -34.92%25.69B | -86.96%1.28B | -13.91%8.81B | -24.65%6.32B | -18.54%9.06B | -25.89%39.47B | -6.14%9.79B | -26.64%10.23B | -50.41%8.39B |
Net non-operating interest income expense | 4.52%-909M | -9.24%-3.73B | 190.06%815M | 25.96%-753M | -265.34%-2.84B | -33.71%-952M | -20.62%-3.41B | -7.10%-905M | -65.37%-1.02B | -9.45%-776M |
Non-operating interest income | -38.33%74M | ---- | ---- | -12.33%128M | ---- | -9.09%120M | ---- | ---- | -16.57%146M | ---- |
Non-operating interest expense | -3.91%958M | 6.22%3.84B | 2.37%950M | -8.89%943M | 16.97%951M | 18.69%997M | 13.35%3.62B | 28.18%928M | 33.20%1.04B | -14.51%813M |
Total other finance cost | -66.67%25M | 43.69%-116M | -436.90%-2.11B | -148.44%-62M | 5,191.89%1.88B | 1,775.00%75M | 43.25%-206M | 2.48%-393M | 884.62%128M | 84.71%-37M |
Other net income (expense) | 328.10%2.65B | -1,522.79%-10.82B | -793.20%-5.65B | 102.65%39M | -566.91%-3.84B | -310.53%-1.16B | -121.61%-667M | -137.11%-632M | -123.74%-1.47B | 474.83%822M |
Gain on sale of security | 352.28%2.6B | -1,547.53%-9.38B | -631.64%-4.81B | 130.42%327M | -642.02%-3.87B | -1,081.90%-1.03B | 147.82%648M | -9.42%904M | -26.32%-1.08B | 126.62%714M |
Earnings from equity interest | 188.17%82M | -106.25%-627M | -368.12%-323M | 90.73%-23M | -754.55%-188M | -365.71%-93M | -221.12%-304M | 43.44%-69M | -875.00%-248M | -144.44%-22M |
Special income (charges) | -2.78%-37M | -5.75%-1.97B | 28.04%-1.67B | -80.27%-265M | --0 | -107.27%-36M | -103.05%-1.86B | -69.20%-2.32B | -110.00%-147M | 35.00%108M |
-Less:Impairment of capital assets | ---- | ---- | ---- | --0 | -109.23%-37M | ---- | ---- | ---- | -69.53%78M | 377.38%401M |
-Less:Other special charges | -78.74%44M | 39.62%666M | -50.94%130M | 425.00%168M | -11.54%161M | 10,450.00%207M | -36.06%477M | -45.13%265M | -70.09%32M | 49.18%182M |
-Write off | 655.56%50M | -42.87%1.53B | ---- | ---- | ---- | -400.00%-9M | 103.80%2.68B | ---- | ---- | ---- |
-Gain on sale of property,plant,equipment | -64.81%57M | -82.39%228M | -73.10%39M | -162.16%-97M | -82.05%124M | -67.34%162M | 13.20%1.3B | 2,316.67%145M | -112.67%-37M | 86.76%691M |
Other non- operating income (expenses) | ---- | 35.37%1.15B | ---- | ---- | 900.00%220M | 47.62%-44M | -83.34%851M | ---- | ---- | -99.20%22M |
Income before tax | 30.98%9.11B | -68.52%11.14B | -143.09%-3.55B | 4.50%8.1B | -104.17%-352M | -36.60%6.95B | -33.87%35.4B | -26.90%8.25B | -38.89%7.75B | -48.41%8.44B |
Income tax | 44.90%3.11B | -65.99%3.54B | -140.08%-788M | -2.56%2.21B | -101.05%-27M | -40.29%2.15B | -37.98%10.4B | -34.62%1.97B | -41.80%2.26B | -51.48%2.58B |
Net income | 24.77%6B | -69.57%7.61B | -144.03%-2.77B | 7.42%5.89B | -105.55%-325M | -34.80%4.81B | -32.00%25B | -24.09%6.28B | -37.61%5.48B | -46.93%5.86B |
Net income continuous Operations | 24.77%6B | -69.57%7.61B | -144.03%-2.77B | 7.42%5.89B | -105.55%-325M | -34.80%4.81B | -32.00%25B | -24.09%6.28B | -37.61%5.48B | -46.93%5.86B |
Minority interest income | -8.70%21M | -30.63%77M | -39.13%14M | -25.00%21M | -38.71%19M | -20.69%23M | -15.91%111M | -25.81%23M | 3.70%28M | 0.00%31M |
Net income attributable to the parent company | 24.93%5.97B | -69.75%7.53B | -144.42%-2.78B | 7.59%5.87B | -105.90%-344M | -34.86%4.78B | -32.05%24.88B | -24.09%6.26B | -37.74%5.46B | -47.07%5.83B |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 24.93%5.97B | -69.75%7.53B | -144.42%-2.78B | 7.59%5.87B | -105.90%-344M | -34.86%4.78B | -32.05%24.88B | -24.09%6.26B | -37.74%5.46B | -47.07%5.83B |
Basic earnings per share | 24.32%0.92 | -69.63%1.16 | -144.94%-0.4314 | 7.14%0.9 | -106.67%-0.06 | -34.25%0.74 | -32.03%3.82 | -24.06%0.96 | -37.31%0.84 | -46.43%0.9 |
Diluted earnings per share | 24.32%0.92 | -69.63%1.16 | -144.94%-0.4314 | 7.14%0.9 | -106.67%-0.06 | -34.25%0.74 | -32.03%3.82 | -24.06%0.96 | -37.31%0.84 | -46.43%0.9 |
Dividend per share | 9.28%0.4766 | -21.23%2.347 | -8.60%0.5027 | -24.31%0.3536 | 36.99%1.0545 | -63.42%0.4362 | -53.81%2.9794 | -57.13%0.55 | -82.01%0.4672 | -45.06%0.7698 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |